Search Results - "Key, Cassandra"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

    A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects by Gu, Kenan, Ruff, Dennis, Key, Cassandra, Thompson, Marissa, Jiang, Shoshanna, Sandison, Taylor, Flanagan, Shawn

    Published in Clinical and translational science (01-07-2022)
    “…Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized,…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Reduced triglycerides and LDL cholesterol from once-weekly administration of the well-tolerated novel FGF21 analogue 0499

    Reduced triglycerides and LDL cholesterol from once-weekly administration of the well-tolerated novel FGF21 analogue 0499 by Dahl, Kirsten, Hansen, Jakob Schiøler, Clausen, Jesper, Palle, Mads Sundby, Key, Cassandra, Andersen, Birgitte

    Published in Journal of hepatology (01-07-2022)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499

    Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499 by Dahl, Kirsten, Friedrichsen, Martin, Ribel-Madsen, Rasmus, Hansen, Jakob Schiøler, Clausen, Jesper, Axelsen, Mads, Palle, Mads Sundby, Key, Cassandra, Murakami, Harumi, Andersen, Birgitte

    Published in Journal of hepatology (01-07-2022)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    A single‐ and multiple‐ascending dose study to evaluate the safety and pharmacokinetics of oral PU‐AD, an epichaperome inhibitor to treat Alzheimer’s disease

    A single‐ and multiple‐ascending dose study to evaluate the safety and pharmacokinetics of oral PU‐AD, an epichaperome inhibitor to treat Alzheimer’s disease by Silverman, Michael, Wallner, Barbara, Key, Cassandra, Duggan, Susan M., Reynolds, Laurie

    Published in Alzheimer's & dementia (01-12-2020)
    “…Background Breakdown of regulatory pathways designed to prevent aggregation and accumulation of disease‐associated proteins contributes to or causes…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    A single‐ and multiple‐ascending dose study to evaluate the safety and pharmacokinetics of oral PU‐AD, an epichaperome inhibitor to treat Alzheimer’s disease: Human/Trial design

    A single‐ and multiple‐ascending dose study to evaluate the safety and pharmacokinetics of oral PU‐AD, an epichaperome inhibitor to treat Alzheimer’s disease: Human/Trial design by Silverman, Michael, Wallner, Barbara, Key, Cassandra, Duggan, Susan M., Reynolds, Laurie

    Published in Alzheimer's & dementia (01-12-2020)
    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    Abstract 2795: A food effect and esomeprazole drug-drug interaction study of RLY-4008, a highly selective FGFR2 inhibitor, in healthy subjects

    Abstract 2795: A food effect and esomeprazole drug-drug interaction study of RLY-4008, a highly selective FGFR2 inhibitor, in healthy subjects by Shen, Jinshan, Sawant, Rishikesh, Blakesley, Rick, Jen, Kai Yu, Ricard, Fabien, Li, Xiaoyan, Key, Cassandra, Karanovic, Djuro

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Background/Introduction: Effective therapies for FGFR2-driven cholangiocarcinoma (CCA) and other advanced solid tumors remain unmet medical needs. RLY-4008 is…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: